StockNews.com Begins Coverage on Cyclacel Pharmaceuticals (NASDAQ:CYCC)

StockNews.com started coverage on shares of Cyclacel Pharmaceuticals (NASDAQ:CYCC) in a research report sent to investors on Thursday morning. The brokerage issued a hold rating on the biotechnology company’s stock.

Cyclacel Pharmaceuticals Price Performance

Shares of CYCC stock traded down $0.49 during mid-day trading on Thursday, hitting $2.00. The company had a trading volume of 566,976 shares, compared to its average volume of 2,344,757. Cyclacel Pharmaceuticals has a 52-week low of $1.30 and a 52-week high of $13.20. The stock’s 50 day moving average price is $2.19 and its 200-day moving average price is $3.58.

Cyclacel Pharmaceuticals (NASDAQ:CYCC) last announced its quarterly earnings results on Tuesday, March 19th. The biotechnology company reported ($6.23) earnings per share for the quarter, topping the consensus estimate of ($6.35) by $0.12. The business had revenue of $0.03 million during the quarter. On average, equities analysts anticipate that Cyclacel Pharmaceuticals will post -18.7 EPS for the current fiscal year.

Cyclacel Pharmaceuticals Company Profile

Cyclacel Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases. The company's lead product includes fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and Plogosertib, a polo-like kinase inhibitor program, which is in Phase 1/2 clinical trial for the treatment of advanced leukemias and solid tumors.